# Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

> **NCT00522990** · PHASE1,PHASE2 · TERMINATED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia
- Myelodysplastic Syndromes
- Myelofibrosis

## Interventions

- **DRUG:** AT9283

## Key facts

- **NCT ID:** NCT00522990
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Recommended Phase II dose determined
- **Last updated:** 2024-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522990, "Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00522990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*